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Abstract: We aimed to simultaneously examine the associations of both essential and non-essential
amino acids with both prevalent and incident type 2 diabetes in a Chinese population. A case-control
study was nested within the Singapore Chinese Health Study. Participants included 144 cases with
prevalent and 160 cases with incident type 2 diabetes and 304 controls. Cases and controls were
individually matched on age, sex, and date of blood collection. Baseline serum levels of 9 essential and
10 non-essential amino acids were measured using liquid chromatography tandem mass spectrometry.
We identified that five essential (isoleucine, leucine, lysine, phenylalanine, and valine) and five
non-essential (alanine, glutamic acid, glutamine, glycine, and tyrosine) amino acids were associated
with the prevalence of type 2 diabetes; four essential (isoleucine, leucine, tryptophan, and valine)
and two non-essential (glutamine and tyrosine) amino acids were associated with the incidence of
type 2 diabetes. Of these, valine and tyrosine independently led to a significant improvement in risk
prediction of incident type 2 diabetes. This study demonstrates that both essential and non-essential
amino acids were associated with the risk for prevalent and incident type 2 diabetes, and the findings
could aid in diabetes risk assessment in this Chinese population.
Keywords: Essential amino acids; non-essential amino acids; type 2 diabetes; serum; LC-MS/MS
1. Introduction
The global prevalence of diabetes among adults is soaring, rising from 4.7% in 1980 to 8.5% in
2014 [1]. Type 2 diabetes comprises 90–95% of diabetes, and is characterized by high blood glucose,
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insulin resistance, and relative insulin deficiency [2]. The pathogenesis of type 2 diabetes is complex
and involves interaction of genetic and environmental influences. Several epidemiologic studies
using metabolomics strategies have reported that the increase of certain essential amino acids such
as branched-chain amino acids (BCAAs) and aromatic amino acids (AAAs) was associated with a
high risk of type 2 diabetes in Western and Asian populations [3–8]. Further, Tilin et al. [9] and
Lee et al. [10] reported ethnical differences in blood levels of BCAAs and AAAs and suggested that
these differences may add explanatory insights into the increased risk of diabetes in multiethnic
cohorts. These observations provide a new angle on the pathogenesis of type 2 diabetes, thus attracting
worldwide attention. However, recent studies have shown conflicting data on the effects of BCAAs on
glucose metabolism and insulin resistance [11–13]. In a recent prospective study, Zheng et al. reported
that high intake of BCAAs is associated with an increased risk of type 2 diabetes in three large cohorts
of US women and men [11], while one study conducted in a Japanese population found that a high
intake of BCAAs is associated with a low risk of type 2 diabetes [13]. Compared to the essential amino
acids, non-essential amino acids can be produced in the body and are less influenced by the dietary
factors, and their concentrations may be more related to the metabolic disorders in type 2 diabetes.
In this study, we thus aimed to simultaneously examine and verify the relation of both essential and
non-essential amino acids with both prevalent and incident type 2 diabetes in a population-based
cohort study, the Singapore Chinese Health Study (SCHS).
2. Results
2.1. Method Validation
A total of 19 amino acids, including 9 essential (histidine, isoleucine, leucine, lysine, methionine,
phenylalanine, threonine, tryptophan, and valine) and 10 non-essential amino acids (alanine, arginine,
asparagine, aspartic acid, glutamic acid, glutamine, glycine, proline, serine, and tyrosine), were
quantified in this study (Supplementary Table S1). The proposed analytical method was validated for
limit of detection (LOD), linearity, recovery, accuracy, and precision (Supplementary Table S2).
2.2. Participant Characteristics
Table 1 shows baseline characteristics of the participants, in which prevalent and incident type 2
diabetes were presented separately. In this study, we divided the cases into prevalent and incident
type 2 diabetes cases according to their baseline HbA1c levels: prevalent cases with HbA1c ≥ 6.5%
(47.5 mmol/mol) and incident cases with HbA1c < 6.5% (47.5 mmol/mol). Cases with prevalent and
incident type 2 diabetes had higher levels of random glucose, BMI, triglycerides and lower levels of
high-density lipoprotein (HDL)-cholesterol than controls at baseline (p ≤ 0.001), and they were also
more likely to report a history of hypertension. As noted, 27.3% participants (166 out of 608) were
fasted before blood collection.
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Table 1. Baseline characteristics of the participants.
Baseline Characteristics
Prevalent Type 2 Diabetes Incident Type 2 Diabetes
Case (n = 144) Control (n = 144) p Value Case (n = 160) Control (n = 160) p Value
HbA1c
% 7.7 ± 1.6 5.6 ± 0.3 5.9 ± 0.4 5.5 ± 0.2
mmol/mol 60.7 ± 12.6 37.7 ± 2.0 41.0 ± 2.8 36.6 ± 1.3
Random glucose (mmol/L) 8.8 ± 4.2 4.9 ± 1.3 <0.001 5.8 ± 2.0 4.9 ± 1.2 <0.001
Age (years) 62.7 ± 6.1 62.7 ± 5.9 0.834 61.6 ± 5.6 61.9 ± 6.0 0.163
Sex, n (%) 1.000 1.000
Male 62 (43.1) 62 (43.1) 79 (49.4) 79 (49.4)
Female 82 (56.9) 82 (56.9) 81 (50.6) 81 (50.6)
BMI (kg/m2) 24.6 ± 3.6 23.1 ± 3.3 <0.001 24.6 ± 3.4 22.6 ± 3.5 <0.001
History of hypertension, n (%) 0.066 <0.001
No 84 (58.3) 99 (68.7) 75 (46.9) 118 (73.8)
Yes 60 (41.7) 45 (31.3) 85 (53.1) 42 (26.3)
Smoking status, n (%) 0.700 0.721
Non-smoker 99 (68.8) 102 (70.8) 106 (66.3) 109 (68.1)
Smoker 45 (31.2) 42 (29.2) 54 (33.7) 51 (31.9)
Alcohol consumption, n (%) 0.733 0.867
< 1 drink/week 125 (86.8) 123 (85.4) 139 (86.9) 140 (87.5)
≥1 drink/week 19 (13.2) 21 (14.6) 21 (13.1) 20 (12.5)
Physical activity, n (%) 0.879 0.689
<0.5 hours/week 118 (81.9) 117 (81.3) 125 (78.1) 122 (76.3)
≥0.5 hours/week 26 (18.1) 27 (18.7) 35 (21.9) 38 (23.7)
Education, n (%) 0.405 0.657
None 37 (25.7) 31 (21.5) 29 (18.1) 26 (16.3)
Primary and above 107 (74.3) 113 (78.5) 131 (81.9) 134 (83.7)
Fasting status, n (%) 0.372 0.360
Non-fasting 96 (66.7) 103 (71.5) 118 (73.8) 125 (78.1)
Fasting 48 (33.3) 41 (28.5) 42 (26.3) 35 (21.9)
HDL-cholesterol (mmol/L) 1.1 ± 0.2 1.2 ± 0.3 <0.001 1.1 ± 0.3 1.2 ± 0.3 <0.001
Triglycerides (mmol/L) 2.6 ± 1.9 2.0 ± 1.3 0.001 2.4 ± 1.3 1.7 ± 0.9 <0.001
Data are presented as mean ± standard deviation for continuous variables, and n (%) for categorical variables. The
p values were calculated by paired t-test for continuous variables and Chi-square test for categorical variables.
2.3. Associations Between Amino Acids and Type 2 Diabetes
Associations between amino acids and the risk for prevalent type 2 diabetes are shown in
Table 2. After adjustment for confounders, including BMI, history of hypertension, smoking status,
HDL-cholesterol, and triglycerides, 10 amino acids were associated with prevalent type 2 diabetes at
p < 0.05, including 5 essential (isoleucine, leucine, lysine, phenylalanine, and valine) and 5 non-essential
(alanine, glutamic acid, glutamine, glycine, and tyrosine) amino acids. All the 10 amino acids were
significant with an FDR cut-off of 0.1. Although 0.05 is commonly used as a cutoff limit for FDR in the
discovery of metabolic signatures, the metabolites with FDR between 0.05 and 0.1 are still considered
marginally significant. To avoid missing potential biomarker candidates associated with risk for type 2
diabetes, we applied 0.1 as the cutoff value for FDR. The associations between amino acids and the risk
for incident type 2 diabetes were shown in Supplementary Table S3. After adjustment for BMI, history
of hypertension, smoking status, HDL-cholesterol, and triglycerides, 6 amino acids were associated
with incident type 2 diabetes at p < 0.05, including 4 essential (isoleucine, leucine, tryptophan, and
valine) and 2 non-essential (glutamine and tyrosine) amino acids. However, none of the 6 amino acids
were significant at FDR < 0.1. Of these, five differential amino acids were common to prevalent and
incident type 2 diabetes, including glutamic acid, tyrosine, and three BCAAs (leucine, isoleucine, and
valine). The associations of 5 common amino acids with prevalent type 2 diabetes were stronger than
those with incident type 2 diabetes, except tyrosine, for which the association with incident type 2
diabetes was more evident.
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Table 2. The associations between amino acids and prevalent type 2 diabetes (n = 144).
Amino Acids OR Across Tertiles (T) a OR Per SD Increment a
T1 T2, OR (95% CI) T3, OR (95% CI) p forTrend FDR OR (95% CI) p Value FDR
Essential amino
acids
Valine 1.00 5.00 (2.05, 12.18) 5.13 (2.05, 12.86) 0.001 0.006 1.85 (1.30, 2.64) 0.001 0.006
Leucine 1.00 2.43 (1.24, 4.73) 2.63 (1.27, 5.48) 0.007 0.033 1.55 (1.12, 2.13) 0.008 0.038
Isoleucine 1.00 2.79 (1.39, 5.62) 2.22 (1.08, 4.57) 0.026 0.068 1.34 (0.98, 1.85) 0.069 0.133
Phenylalanine 1.00 1.99 (1.03, 3.84) 2.12 (1.05, 4.26) 0.030 0.068 1.44 (1.05, 1.96) 0.022 0.073
Lysine 1.00 0.88 (0.45, 1.74) 2.28 (1.11, 4.68) 0.032 0.068 1.42 (1.04, 1.94) 0.027 0.073
Methionine 1.00 2.75 (1.39, 5.46) 1.86 (0.92, 3.80) 0.077 0.124 1.21 (0.90, 1.65) 0.209 0.265
Threonine 1.00 0.83 (0.42, 1.63) 0.54 (0.27, 1.08) 0.085 0.124 0.81 (0.62, 1.07) 0.134 0.219
Tryptophan 1.00 0.62 (0.31, 1.25) 1.79 (0.78, 4.14) 0.222 0.301 1.43 (0.97, 2.11) 0.070 0.133
Histidine 1.00 1.49 (0.75, 2.93) 0.85 (0.44, 1.65) 0.644 0.723 0.81 (0.62, 1.07) 0.138 0.219
Non-essential
amino acids
Glutamic acid 1.00 2.96 (1.37, 6.39) 4.04 (1.79, 9.12) 0.001 0.006 1.89 (1.34, 2.67) <0.001 0.006
Alanine 1.00 1.73 (0.82, 3.65) 3.41 (1.63, 7.14) 0.001 0.006 1.73 (1.23, 2.42) 0.001 0.006
Glutamine 1.00 0.66 (0.27, 1.62) 0.32 (0.12, 0.87) 0.017 0.057 0.65 (0.44, 0.97) 0.035 0.083
Glycine 1.00 0.51 (0.26, 1.00) 0.47 (0.26, 0.87) 0.018 0.057 0.73 (0.55, 0.96) 0.024 0.073
Tyrosine 1.00 1.82 (0.90, 3.66) 2.12 (1.03, 4.37) 0.044 0.084 1.23 (0.90, 1.68) 0.186 0.252
Serine 1.00 1.27 (0.70, 2.32) 1.81 (0.93, 3.52) 0.083 0.124 1.21 (0.91, 1.60) 0.186 0.252
Asparagine 1.00 1.20 (0.63, 2.29) 0.66 (0.32, 1.36) 0.299 0.379 0.86 (0.63, 1.18) 0.362 0.430
Arginine 1.00 0.95 (0.47, 1.90) 0.86 (0.46, 1.62) 0.647 0.723 0.92 (0.71, 1.20) 0.541 0.605
Proline 1.00 1.70 (0.83, 3.47) 1.00 (0.49, 2.07) 0.935 0.970 1.00 (0.76, 1.32) 0.997 0.997
Aspartic acid 1.00 0.67 (0.33, 1.38) 1.04 (0.43, 2.50) 0.970 0.970 1.05 (0.78, 1.41) 0.767 0.810
Prevalent cases were defined as those had HbA1c ≥ 6.5% (47.5 mmol/mol) but did not report to have diagnosed
diabetes at baseline when blood samples were collected (1999–2004), while reported to have diagnosed diabetes
during the follow-up (2006–2010). a Odds ratio (OR) with 95% confidence interval (CI) and p values were calculated
by conditional logistic regression after adjustment for BMI, history of hypertension, smoking status, HDL-cholesterol,
and triglycerides.
In our study, certain amino acid changes due to fasting status were observed (Supplementary
Table S4). However, stratification by fasting status showed that fasting had no effect on the
associations between amino acids with prevalent and incident type 2 diabetes (p for interaction
> 0.5) (Supplementary Tables S5 and S6). This is possibly because the proportion of type 2 diabetes
cases was equally distributed among fasting and non-fasting participants (p > 0.05) (Table 1). They
are the reasons why we did not include fasting status in the models. In contrast, we reasoned that
smoking is an important risk factor for type 2 diabetes and thus included it in the models.
2.4. Predictive Value of Amino Acids for Incident Type 2 Diabetes
We evaluated the predictive performance of amino acids for the risk of incident type 2 diabetes
using c- statistics, and IDI and NRI indexes (Table 3). Adding the 19 amino acids individually did
not significantly improve AUCROC values compared to base model of BMI, history of hypertension,
smoking status, HDL-cholesterol, and triglycerides, whereas IDI and NRI statistics showed that valine
and tyrosine could improve risk reclassification of incident type 2 diabetes at p < 0.05. In addition to
individual amino acid, we explored the predictive performance of certain amino acid combinations
through binary logistic regression, including combinations of 6 amino acids associated with incident
type 2 diabetes (combination 1), 9 essential amino acids (combination 2), 10 non-essential amino acids
(combination 3), and all the 19 amino acids (combination 4). We found that all the 4 combinations could
significantly improve risk reclassification of incident type 2 diabetes with a p < 0.01 in IDI and NRI
statistics, yet only the combination 4 led to a significant increase in area under the receiver operating
characteristic curve (AUCROC) value (p = 0.04).
Metabolites 2019, 9, 14 5 of 10
Table 3. Potential of amino acids for risk prediction of incident type 2 diabetes (n = 160).
Amino acids
C-Statistics a IDI NRI
AUC (95%CI) p Value p Value p Value
Essential
Valine 0.76 (0.70, 0.81) 0.34 0.03 0.01
Tryptophan 0.75 (0.70, 0.81) 0.51 0.05 0.09
Phenylalanine 0.76 (0.70, 0.81) 0.33 0.07 0.06
Leucine 0.75 (0.70, 0.80) 0.46 0.08 0.03
Isoleucine 0.75 (0.70, 0.80) 0.82 0.20 0.91
Histidine 0.75 (0.70, 0.80) 0.60 0.31 0.02
Methionine 0.75 (0.70, 0.80) 0.88 0.44 0.99
Lysine 0.75 (0.70, 0.80) 0.94 0.59 0.15
Threonine 0.75 (0.69, 0.80) 0.61 0.91 0.99
Non-essential
Tyrosine 0.76 (0.71, 0.81) 0.21 0.02 0.01
Aspartic acid 0.75 (0.70, 0.81) 0.36 0.10 0.50
Glycine 0.75 (0.70, 0.81) 0.38 0.14 0.99
Alanine 0.75 (0.70, 0.80) 0.62 0.31 0.31
Glutamic acid 0.75 (0.70, 0.80) 0.76 0.38 0.37
Arginine 0.75 (0.69, 0.80) 0.92 0.69 0.50
Proline 0.75 (0.70, 0.80) 0.56 0.77 0.37
Serine 0.75 (0.69, 0.80) 0.87 0.80 0.58
Glutamine 0.75 (0.70, 0.80) 0.89 0.83 0.65
Asparagine 0.75 (0.69, 0.80) 0.08 0.99 0.65
Combinations
Combination 1 0.76 (0.71, 0.82) 0.15 <0.01 <0.01
Combination 2 0.77 (0.72, 0.82) 0.12 <0.01 <0.01
Combination 3 0.77 (0.72, 0.82) 0.07 <0.01 <0.01
Combination 4 0.78 (0.73, 0.83) 0.04 <0.01 <0.01
IDI, integrated discrimination improvement; NRI, category-free net reclassification improvement. Combination 1: 6
amino acids associated with incident type 2 diabetes, including isoleucine, leucine, tryptophan, valine, glutamine,
and tyrosine. Combination 2: 9 essential amino acids, including histidine, isoleucine, leucine, lysine, methionine,
phenylalanine, threonine, tryptophan, and valine. Combination 3: 10 non-essential amino acids, including alanine,
arginine, asparagine, aspartic acid, glutamic acid, glutamine, glycine, proline, serine, and tyrosine. Combination 4:
all the 19 measure amino acids. a AUC increment of amino acids after adding in the basic model (AUC = 0.75, 95%
CI [0.69, 0.80]) of BMI, history of hypertension, smoking, HDL-cholesterol, and triglycerides.
3. Discussion
In this case-control study, we simultaneously quantified 9 essential and 10 non-essential amino
acids using LC-MS/MS. The increase of 6 essential (isoleucine, leucine, lysine, phenylalanine,
tryptophan, and valine) and 3 non-essential (alanine, glutamic acid, and tyrosine) amino acids was
associated with a higher risk for prevalent and/or incident type 2 diabetes. On the other hand,
accumulation of glutamine and glycine was associated with a lower risk of type 2 diabetes. Notably,
we found that these associations were influenced by random glucose levels. With further adjustment
for random glucose, none of these amino acids remained significant associations with type 2 diabetes.
Moreover, we examined the predictive performance of amino acids for type 2 diabetes and found that
valine and tyrosine showed positive predictive value for diabetes risk in this Chinese population.
Essential amino acids such as BCAAs are mainly derived from dietary intake and are metabolized
in skeletal muscle and adipose tissue [14]. Numerous epidemiologic studies have identified
blood BCAAs as among the most consistent and important metabolites associated with insulin
resistance [3,15–17]. In consistent with these studies, we found that BACCs (isoleucine, leucine,
and valine) were significantly increased in prevalent and incident type 2 diabetes cases compared to
controls. Although not completely understood, there exists several possible mechanisms underlying
the association between BCAAs and the risk of type 2 diabetes. First, a recent study by Pedersen
et al. shown that altered intestinal microbiota impacted BCAA levels and may contribute to insulin
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resistance [18]. Further, BCAAs can increase skeletal muscle glucose uptake and stimulate glycogen
synthesis in an insulin-independent manner through phosphatidylinositol 3-kinase or protein kinase
C [19]. In addition, the interplay of adipose tissue, BCAA metabolism, and glucose homeostasis was
reported recently [20]. BCAAs may produce more catabolic intermediates such as propionyl CoA and
succinyl CoA, leading to accumulation of incompletely oxidized fatty acids and glucose.
AAAs, particularly phenylalanine and tyrosine, have been reported to be elevated together with
BCAAs in obesity-related insulin resistance [3,15,21,22]. In line with these studies, we found that
phenylalanine and tyrosine were significantly increased in prevalent and/or incident type 2 diabetes
cases compared to controls. In addition, tryptophan was found to be significantly increased in incident
type 2 diabetes cases compared to controls in our study. Tryptophan can be metabolized to several
kinds of physiologically active metabolites such as kynurenine, kynurenic acid, and serotonin via two
metabolic pathways: tryptophan–kynurenine and tryptophan–methoxyindole. The changes in the two
pathways have been related to several pathophysiological mechanisms of type 2 diabetes [23].
Besides well-recognized BCAAs and AAAs, we identified four non-essential amino acids (alanine,
glutamic acid, glutamine, and glycine) associated with prevalent and/or incident type 2 diabetes.
Among these four amino acids, alanine and glutamic acid were positively associated with risk of type
2 diabetes; glutamine and glycine were negatively associated. The finding of inverse associations
between glutamine and glycine and the risk for type 2 diabetes is in line with a recent meta-analysis [16].
Alanine has recently been associated with future hyperglycemia and the risk for diabetes [24–26].
Glutamic acid is derived from BCAAs, catalyzed by branched-chain aminotransferase. A report from
the Framingham offspring study showed that glutamic acid was positively associated with insulin
resistance [27]. In this study, the increase of glutamic acid was strongly associated with the risk for
prevalent and incident type 2 diabetes.
The strength of this study is its prospective design and hence the presumed lack of recall bias in
exposure data prior to type 2 diabetes diagnosis. Furthermore, the roles of essential and non-essential
amino acids were estimated in parallel in this study. However, several limitations in our study exist.
First, more than 70% of serum samples were non-fasting, and may thus affect the metabolite levels.
To address this limitation, we conducted a stratified analysis by fasting status and no significant
differences were observed between fasting and non-fasting samples. Second, the levels of essential
amino acids are partly influenced by the dietary habits, yet the information regarding the diet was
not available for further investigation. Third, the samples size is relatively small, and the potential
of amino acids for risk prediction of type 2 diabetes in Chinese need to be validated externally in a
large population.
4. Materials and Methods
4.1. Chemicals and Reagents
LC-MS grade methanol, acetonitrile, formic acid, ammonium formate, and standards including
amino acid standard mixture (AAS18), tryptophan, glutamine, and asparagine were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Isotopically labeled amino acid mix standard (MSK-A2-1.2) was
purchased from Cambridge Isotope Laboratories (Tewksbury, MA, USA). Distilled water was purified
“in-house” using a Milli-Q purification system (Bedford, MA, USA).
4.2. Study Population
The participants were from the SCHS. Detailed information of recruitment and follow-up visits
for SCHS has been published previously [8,28]. Briefly, 63,257 Chinese aged 45–74 years were recruited
in 1993-1998. The first follow-up visit was conducted in 1999–2004, and 32,575 participants donated
the morning blood samples, in which fasting was not required. The second follow-up visit was
conducted in 2006–2010. Because of the logistical and funding constraints of this study, we randomly
selected 608 participants for this study, including 304 cases and 304 controls. The cases were free of
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diagnosed diabetes, cardiovascular disease, and cancer during the first visit when blood was collected
(baseline), while reported to have type 2 diabetes during the second visit. The controls were free
of aforementioned diseases both at first and second visits. The age (±3 years), sex, and date of
blood collection (±6 months) of cases and controls were individually matched. The baseline serum
samples were used in this study. All participants voluntarily joined this study, gave informed consents,
and completed questionnaires that provided information including age, sex, demographical factors,
lifestyle habits, and medical history. This study was approved by the Institutional Ethics Review Board
at the National University of Singapore (ethic code: NUS-IRB code 06-027).
4.3. Prevalent and Incident Type 2 Diabetes: Patient Regrouping
In Singapore, diagnostic tests of diabetes at the time of two visits (1999–2004 and 2006–2010) were
made according to the 1997 American Diabetes Association (ADA) criteria [29], which were based on
symptoms plus random glucose concentrations, fasting glucose concentrations or 2-h glucose tolerance
tests. Here, random glucose concentration presents a blood glucose measurement that was carried out
either with blood taken from a fasting status, or a non-fasting status during the study visit. In 2010,
HbA1c ≥ 6.5% (47.5 mmol/mol) was proposed by ADA as an additional diagnostic criterion [30]. In
line with the update of diagnostic criteria, we divided the 304 cases into prevalent and incident type 2
diabetes cases according to their baseline HbA1c levels: cases with HbA1c ≥ 6.5% (47.5 mmol/mol)
at baseline were defined as prevalent cases (n = 144); cases with HbA1c < 6.5% (47.5 mmol/mol) at
baseline were classified as incident cases (n = 160). HbA1c values in the controls were all < 6.0%
(42.1 mmol/mol).
4.4. Lipid Assays
Blood concentrations of-cholesterol and triglycerides were measured using colorimetric method
on a chemistry analyzer (AU5800; Beckman Coulter, Brea, CA, USA).
4.5. Amino Acid Quantification
Serum samples (50 µL) were diluted with 50µl of distilled water containing isotope labeled amino
acid mix standard (75 µM) as internal standards. The mixture was treated by 500 µL of ice-cold
methanol for protein precipitation. After centrifugation at 20,817 g for 15 min at 4◦C, the supernatant
fraction was filtered by Thermo Scientific™ national 750µL micro-centrifugal filters (PTFE membrane,
0.2 µm pore size, non-sterile). The filtrate was dried by 99.9% purity of nitrogen (N2) and reconstituted
in 200 µL of acetonitrile/water (90:10, v/v) before analysis.
Quantitative analysis of amino acids was performed on an Agilent 1200 HPLC system (Waldbronn,
Germany) coupled to a 6410 Triple Quadrupole mass spectrometer (Waldbronn, Germany) equipped
with an electrospray ionization source in positive ion mode. Amino acids were separated by using
an Acquity UPLC BEH Amide column (2.1 mm × 100 mm, 1.7 µm, Waters). The mobile phases A
(30% acetonitrile with 0.1% formic acid and 10 mmol/L ammonium formate) and B (95% acetonitrile
with 0.1% formic acid and 10 mmol/L ammonium formate) were employed. The gradient program
was: 0–1 min, 100% B; 1–2 min, 100–92% B; 2–10 min, 92–85% B; 10–12 min, 85–60% B; 12–14 min,
60–40% B; 14–15 min, 40–15% B; 15–19 min, 15%B; 19–19.5 min, 15–100% B. The flow rate was set at
0.5 mL/min. The column temperature and injection volume were set at 40◦C and 5 µL, respectively.
The mass spectrum was acquired in the multiple reaction monitoring (MRM) mode with a capillary
voltage of 3500 V, gas temperature of 350◦C, gas flow of 12 L/min and nebulizer nitrogen gas flow
rate of 30 psi. The retention time, MRM transition, fragmentor voltage, and collision energy (CE) are
shown in Supplementary Table S1.
All the 304 paired samples were analyzed blindly in 8 completely independent batches, i.e.,
38 paired samples in each batch. The stable isotope labeled internal standards were used in all the
sample extractions and for calibration. The quality control (QC) samples were prepared by spiking
certain amount native and labeled standards into a pooled plasma from all participants, and six QCs
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were analyzed along with the samples in each batch to ensure the reliability of the method and the
instrument stability.
4.6. Statistical Analysis
Demographic and clinical variables of participants were presented as mean ± standard deviation
(SD) for continuous data, and proportions for categorical data. Their differences between cases and
controls were tested using paired t-test for continuous variables and chi-square test for categorical
variables. All the amino acids measured were detected in all of the 608 serum samples, i.e., there was
no missing value. Odds ratio (OR) with 95% confidence interval (CI) and p value for the associations
between amino acids and type 2 diabetes were calculated by conditional logistic regression models,
with adjustment for confounding factors, including BMI, history of hypertension, smoking status,
HDL-cholesterol, and triglycerides. The OR was represented both as tertiles and per SD increment for
each amino acid, and p value was corrected for multiple testing via false discovery rate (FDR) using
the Benjamini-Hochberg method. The correlations of amino acids with random glucose and HbA1c
levels were examined in controls using Pearson partial correlation analysis, adjusting for age, sex,
and BMI. The c-statistic (i.e., the area under the receiver operating characteristic curve (AUCROC))
was calculated to assess the predictive utility of each metabolite by examining the improvement in
discrimination. Because of the limitation of AUCROC: it is insensitive to detect clinically important
risk differences [31], we evaluated the integrated discrimination improvement (IDI) and category-free
net reclassification improvement (NRI) indexes as well. Statistical analyses were performed using
IBM SPSS Statistics 24 and Stata version 14.0. A two-sided p <0.05 or FDR <0.1 was considered as
statistically significant.
5. Conclusions
In conclusion, this study demonstrates the previous reports of strong associations between
essential amino acids, particularly BCAAs and AAAs, and the risk for prevalent and incident type 2
diabetes. Further, the associations of non-essential amino acids and the risk for prevalent and incident
type 2.
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